Catabasis Pharmaceuticals & Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive & Drug-Resist...
August 04 2020 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, announced today it entered into an
agreement with the Bill & Melinda Gates Medical Research
Institute (Gates MRI), a non-profit biotechnology organization, to
assess CAT-5571 as a potential oral therapy to promote autophagy
and clear persistent lung infections in patients with both
drug-sensitive and drug-resistant tuberculosis (TB). Catabasis
granted Gates MRI a non-exclusive license to CAT-5571, and will
furnish samples of CAT-5571 to conduct this preclinical
collaboration research program.
Mycobacterium tuberculosis (Mtb) is known to cause TB. CAT-5571
will be studied alone and in combination with the standard of care
regimen in cell and animal models of Mtb infection to determine the
potential for CAT-5571 to induce autophagy and encourage Mtb
elimination as well as to assess its contribution to TB drug
regimens and durations.
In previous preclinical studies, CAT-5571 was shown to restore
autophagy in mouse and human cells with the delta508-CFTR mutation
and promote the clearance of bacteria, including Mycobacterium
abscessus, from these cells. Evidence suggests that autophagy plays
a crucial role in antimycobacterial resistance in TB by acting as
an alternative mechanism to control Mtb infection in macrophages,
as well as to defend and counteract Mtb evasion strategies.
“We are thrilled to work with Gates MRI to expand our
understanding of CAT-5571,” said Andrew Nichols, Ph.D., Chief
Scientific Officer of Catabasis. “We look forward to learning more
about how autophagy could potentially benefit communities with
tuberculosis. We hope that a new treatment option may someday
benefit those affected, especially those with TB resistant to
current treatments.”
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead
program is edasalonexent, an NF-kB inhibitor in Phase 3 development
for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our Phase 3 PolarisDMD trial,
please visit www.catabasis.com.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
anticipated results from the research program and CTA-5571 as a
potential treatment for TB and other statements containing the
words “believes,” “anticipates,” “plans,” “expects,” “may” and
similar expressions, constitute forward-looking statements under
applicable securities laws and regulations. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
risks and uncertainties related to the impact of the COVID-19
pandemic, uncertainties inherent in the initiation and completion
of research programs and studying a potential therapy for a
potential new indication, and other factors discussed in the “Risk
Factors” section of the Company’s Quarterly Report on Form 10-Q for
the period ended March 31, 2020, which is on file with the
Securities and Exchange Commission, and in other filings that the
Company may make with the Securities and Exchange Commission in the
future. In addition, the forward-looking statements included in
this press release represent the Company’s views as of the date of
this press release. The Company anticipates that subsequent events
and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200804005154/en/
Catabasis Investor and Media
Contact Andrea Matthews Catabasis Pharmaceuticals, Inc. T:
(617) 349-1971 amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2024 to May 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From May 2023 to May 2024